


Advancing Health Research Through Collaboration

Annual Report
2014-2015



BIOGRID
AUSTRALIA

BioGrid Facts

 **32** Number of Members at 30 June 2015
representing
60 institutions

 **138**
Journal publications to date

 **88**
Approved active audit/research
projects during 2014-15

Thirty-five
 Current Institution Ethics Approvals
at 30 June 2015

1.36 million
Individual patients available through BioGrid



Conferences


17 Conference presentations
during 2014-15

NATIONAL = Canberra, Darwin,
Melbourne and Sydney

INTERNATIONAL = Prague, Czech
Republic; Goa, India; Chiba, Japan;
Kuala Lumpur, Malaysia

Contents

Members and Collaborators	2
Chairman's Report	4
Chief Executive Officer's Report	5
About BioGrid	6
New Members, New Data, New Opportunities	8
VCCC Uses Biogrid for Policy and Practice Research	10
BioGrid is Facilitating Diabetes Research across Australia	11
Roche Seeks Insights to Move Toward Personalised Care	12
CART-WHEEL Retains its Consumer Focus	14
BioGrid's Student Placement Success	15
Directors' Report	16
Financial Report	20
Directors' Declaration	26
Auditor's Report	27



Members and Collaborators

BioGrid Australia Ltd is a not for profit company limited by guarantee. Its members are health services, universities and research institutes. At the time of this report, BioGrid's overarching evergreen collaboration agreement has been executed with 32 institutions (representing 60 sites across Australia) covering the management of governance, intellectual property, data access, undertaking projects, commercialisation and publications.



ACT Health
Canberra Hospital



Alfred Health
The Alfred
Caulfield Hospital
Sandringham Hospital



Austin Health
Austin Hospital
Heidelberg Repatriation Hospital



Baker IDI Heart and Diabetes Institute



Ballarat Health Services
Ballarat Base Hospital
Queen Elizabeth Centre



Barwon Health
Geelong Hospital



Bendigo Health
Bendigo Hospital



Central Adelaide Local Health Network
Royal Adelaide Hospital
The Queen Elizabeth Hospital



Eastern Health
Angliss Hospital
Box Hill Hospital
Healesville Hospital
Maroondah Hospital



Goulburn Valley Health
Goulburn Valley Hospital



Hudson Institute of Medical Research



Latrobe Regional Hospital



Melbourne Health
The Royal Melbourne Hospital



Metro North Hospital and Health Service
Royal Brisbane and Women's Hospital
Prince Charles Hospital



Metro South Hospital and Health Service*
Princess Alexandra Hospital



Monash Health
Monash Medical Centre, Clayton
Monash Medical Centre, Moorabbin
Casey Hospital
Dandenong Hospital



Monash University*



Murdoch Childrens Research Institute



Northern Health
The Northern Hospital



Peninsula Health
Frankston Hospital
Rosebud Hospital



**Peter MacCallum
Cancer Centre**



**Radiation Oncology
Victoria**



**St John of God
Health Care**

Ballarat, Bendigo, Berwick, Bunbury,
Burwood, Geelong, Geraldton, Midland,
Murdoch, Mt Lawley, Richmond,
Subiaco and Warrnambool Hospitals



**St Vincent's Hospital,
Melbourne**



**Tasmanian Government
Department of Health
and Human Services**

Royal Hobart Hospital
Launceston General Hospital



**The Royal
Children's Hospital**



**The Royal Women's
Hospital**



**The University of
New South Wales**



**The University of
Melbourne**



**The Walter and Eliza Hall
Institute of Medical
Research**



**Victorian Comprehensive
Cancer Centre**



Western Health

Western Health
Footscray Hospital
Sunshine Hospital
The Williamstown Hospital

* Non-member collaborator

Chairman's Report



Bryan Williams

Following the excitement of our tenth anniversary year, 2014-15 was a year of hard work and consolidation. We have continued to grow our membership, increased the number of publications produced utilising BioGrid and focused on improving our financial standing.

Since its inception in 2003, BioGrid has transitioned from an unincorporated joint venture of collaborative institutions to a not for profit company limited by member guarantee with 28 data types, 57 data custodians and 28 connected institutions. We have productive contracts with a number of private companies and we are also progressing toward signing up international institutions.

This year we welcomed three new members: the Victorian Comprehensive Cancer Centre; St John of God Healthcare; and the Hudson Institute of Medical Research. We are very excited about working with our members to further investigate best practice treatments and to advance cancer care by linking data to facilitate personalised medicine.

I would like to thank the many people who have contributed to BioGrid's successes over the years, especially the BioGrid staff, clinical leaders and researchers for their hard work and perseverance over the past 11 years. A special thanks to the executive management team; Maureen Turner (Chief Executive Officer), A/Prof Peter Gibbs (Head, Clinical Research), Dr Leon Heffer (Head, Data Services) and Naomi Rafael (Head, Technology and Systems), for their dedication and commitment to the on-going operation and development of BioGrid.

Since 2003 Melbourne Health has continued to act as secretariat and home for BioGrid. This year we relocated to our new home in the Centre for Medical Research in Royal Parade and the arrangement is working well for all concerned.

After 10 years of close involvement with BioGrid, Rob Merriel, one of BioGrid's founding directors, stepped down from the Board during December 2014. Rob has been involved with BioGrid since its establishment, initially as a representative on the BioGrid Management

Committee and then as the Committee's Chair over four years. From 2009 Rob became a founding Director and Company Secretary of BioGrid and in 2010 became the inaugural Chair of the Audit and Risk Committee until his retirement from the Board.

I wish to personally thank Rob for his outstanding contribution to BioGrid since its inception, and on behalf of the Board sincerely thank Rob for the support he has provided to the company and his fellow directors over the years.

During January 2015 we welcomed David Polonsky as a BioGrid Director. David is the Director of Business Advisory at Moore Stephens (formerly Nexia Melbourne) and brings extensive financial skills and knowledge to the Board.

Finally, I would like to acknowledge the commitment and dedication of my fellow longer standing Directors, Dr Julian Clark, Dr Fernando Martin-Sanchez and Chris Arnold, all of whom have worked tirelessly setting and achieving fiscal and strategic goals for BioGrid.

With its unique combination of federated technology, collaboration, ethics approval and data governance processes that facilitate biomedical research, opportunities abound for BioGrid. As our reputation grows and we continue hard work and planning, we move toward our key objective of become sustainable by 2015-16.

The last year has seen growth and stability, a winning combination that I believe will allow BioGrid to continue as the nation's premium health data real-time linkage research platform.



Chief Executive Officer's Report

BioGrid is unique in the health informatics sector in that it operates a real-time federated data integration platform across multiple organisations, jurisdictions and disease settings where privacy and security of biomedical data and intellectual property of data custodians is ethically and legally protected. BioGrid now has 11 years of experience operating in this space, where its recognition continues to grow.

This collaborative model is known throughout the research community as a trustworthy source of primary and secondary data, independent of government and the corporate sector. Independence allows BioGrid to support members and collaborators across jurisdictions and diseases and facilitate appropriate engagement with industry without compromising the collaboration's intent or objectives.

This year we were delighted to enter into a new collaboration with Roche for the **Treatment of Advanced Breast Cancer in the HER2 Positive Australian Patient (TABITHA)** study. This multi-site registry will collect data related to the management of HER2+ breast cancer in a routine clinical practice patient population. Information collected will include: the duration of therapy; the rationale for any change in treatment; use of anti-HER2 therapies; rate of cardiotoxicity; and approach to cardiac monitoring. As HER+ breast cancer is associated with an increased rate of central nervous system metastases, the data of patients who subsequently develop brain metastases will also be recorded. As with all studies BioGrid conducts with industry partners, the data collected are owned by the participating sites and the clinicians involved are free to utilise these data for their own audit and research purposes.

During the year BioGrid was invited to run a workshop adjunct to the annual Human Genome Organisation (HUGO) conference, held in Kuala Lumpur, Malaysia during March 2015. The invitation was extended by Professor Zilfalil Alwi, the lead on the establishment of the Human Variome Project (HVP) ASEAN Node. BioGrid has the HVP Australian Node database linked to the BioGrid platform.

Dr Leon Heffer and I ran the half day workshop on BioGrid Australia's federated data sharing model that covered the fundamentals of a successful federated data platform, managing data access and usage within a federated model and applying a federated data sharing model to countries in South East Asia. Attendees included staff from Malaysian Ministry of Health, four Malaysian universities, one Malaysian hospital as well as representatives from other countries in the HVP ASEAN Node, namely, Brunei, Singapore, Thailand and Vietnam. There was considerable interest from attendees about how to enable data sharing. However it was apparent from discussion during the workshop that any governance framework for data sharing across South East Asia would need to meet individual nations' legislative and ethical requirements.

New linkages will support greater participation in research in Australia in a bid to accelerate the development of targeted therapies for patients. The future is looking very promising for BioGrid and its members and collaborators as we work towards achieving our goal of financial sustainability next year.


I would like to acknowledge the BioGrid Member Management Committee for their ongoing support and contribution to BioGrid, as well as the Scientific Advisory Committees for their support. The achievements over the past year, as outlined in this report, would not have been possible without the commitment from each member of the BioGrid team; thank you for your dedication to the organisation and its objectives.


About BioGrid

Data governance, security and ethics are at the core of BioGrid's federated data sharing platform that securely links patient level clinical, biospecimen, genetic and imaging data sets across multiple sites and diseases for the purpose of medical research. BioGrid specialises in making relevant data, most of which reside within the hospital environment, available to authorised researchers to dynamically extract and analyse data from multiple sources whilst protecting patient privacy.

In the health sector, BioGrid is a trusted independent virtual real-time federated clinical data repository. Investment in BioGrid has facilitated a combination of technology, collaboration and ethics approval processes for data sharing that exist nowhere else in the world.

For more information on how BioGrid works, what data is linked to BioGrid and how to access data, go to **www.biogrid.org.au**





1. Patient information is recorded in one or more data sources (i.e. databases, spreadsheets), which are stored on a collaborating institution's computer network. This information comprises clinical health information data and identifiers.
 - 1a. Clinical health information data are the collection of facts and opinions about an individual's health and wellbeing. Treatment details are an example of clinical health information data.
 - 1b. Identifiers are the data items, which identify the individual who is described within a patient record. A patient's name is an example of an identifier.
 2. The patient information is copied into replica data sources, which are stored on the collaborating institution's Local Research Repository (LRR), on a nightly basis or frequency agreed by the collaborating institution.
 3. A limited set of identifiers from each new patient record are sent from the replica data sources to BioGrid Australia's Linkage Key Federator (LKF) via a secure encrypted Virtual Private Network (VPN) connection.
 4. The Linkage Key Federator (LKF) forwards the identifiers to BioGrid Australia's Linkage Key server. This server hosts the Unique Subject Identifier (USI) database.
 5. The identifiers are compared with the USI database's records to establish whether data about the patient already exists within a BioGrid-linked data source.
If a match is found for a patient's data, the patient has previously been allocated a USI. If no match is found for a patient's data, the patient's set of identifiers and a new USI are written to the USI database.
 6. The USIs for the matching and non-matching patients are sent back to the LKF.
 7. The USIs are sent back to the LRR via a secure encrypted VPN connection and stored with their associated clinical health information data.
 8. Once authorised access via the BioGrid Australia Data Access Application System has been provided to the researcher, they can commence querying the de-identified data they have approval to access.
 9. The researcher submits a data query to BioGrid Australia's statistical analysis (SAS) computer via the Internet.
 10. The SAS computer forwards the query to the FDI.
 11. The FDI requests the specified data from each of the relevant LRRs via a secure encrypted VPN connection.
 12. The clinical health information data and USIs from applicable patient records are sent to the FDI via a secure encrypted VPN connection. These data are combined into a temporary table. The table is removed from the FDI upon completion of the query.
 13. The SAS computer reads and processes data from the temporary table.
 14. The SAS computer presents the results of the query to the researcher.
- BioGrid provides alternative matching methodology referred to as exact matching using a cryptographic hashing function when individual identifiers cannot be brought together in one place for comparison.
- ⬆ Highly secure hash generating software is installed at collaborating institution. The hashing algorithm is run at collaborating institution's site on the replica data sources. A unique hash value is created for each set of identifying patient data. No identifying information ever leaves the source site.
 - ⬇ Unique hash value from each new patient record is sent from the replica data source to BioGrid Australia's Linkage Key Federator (LKF) via a secure encrypted Virtual Private Network (VPN) connection. No identifying information ever leaves the source site.
 - ⦿ The LKF synchronises its matches with the BioGrid Australia's Linkage Key server. This server hosts the Unique Subject Identifier (USI) database.

New Members, New Data, New Opportunities

BioGrid is delighted to welcome the Victorian Comprehensive Cancer Centre (VCCC), the Hudson Institute of Medical Research (Hudson) and St John of God Health Care as members.



St John of God Health Care

St John of God is a leading health care provider with both public and private health care facilities across Australia. They have a history of pursuing high quality and ethical research that enhances clinical practice. The health service's focus is on translational research – as they say from 'bench to bedside' – to improve outcomes for patients. With BioGrid's application to translational research, we are an obvious choice for the group.


The St John of God group operates 18 hospitals in Australia and New Zealand and also offers pathology services. Their private hospitals are our first private-sector members and we very much look forward to working with them to progress cross-sectoral translational medical research.



Hudson

Hudson is the result of the successful amalgamation of Monash Institute of Medical Research and Prince Henry's Institute and it boasts a combined 75 years of research experience. It specialises in driving cutting edge research into prevention, diagnosis and treatment of human health problems.

Hudson is one of three partners in the Monash Health Translational Precinct (MHTP). The MHTP's other members are Monash Health and Monash University, both BioGrid members. The collaboration aims to strengthen links between education and training, basic and clinical research, and patient care. It is strongly focused on translational research and delivering innovative health care solutions – a clear fit for BioGrid.



VCCC

In addition to being an impressive new \$1 billion purpose-built facility for cancer research, treatment, education and care, the VCCC is a powerful alliance of Australia's premier cancer programs. The Alliance, members of the VCCC, includes:

- Peter MacCallum Cancer Centre
- The Royal Melbourne Hospital
- The University of Melbourne
- The Royal Women's Hospital
- The Walter and Eliza Hall Institute
- The Royal Children's Hospital
- Western Health
- St Vincent's Hospital
- Austin Health
- Murdoch Childrens Research Institute

Its vision is to:

"save lives through the integration of cancer research, education and patient care. Through innovation and collaboration, the VCCC will drive the next generation of improvements in the prevention, detection and treatment of cancer."

All the VCCC's members are also BioGrid members and BioGrid will be integral in helping the VCCC's members to collaborate in order to achieve the vision.

New opportunities

New members bring new data and fresh opportunities for innovative research. They also bring new ideas and we welcome input from our members about how to improve BioGrid or better utilise its extraordinary capacity.

All of our new members have a strong emphasis on translational research. BioGrid's ability to link real-time patient data, in an ethically approved manner, will be instrumental in driving that agenda. Now investigators can query new data sets, access more patient information to increase statistical power and deliver answers to questions direct to treating clinicians.

In time, BioGrid will provide treating clinicians at those centres, and of course those of our existing members, with immediate access to information that will influence their treatment decisions. BioGrid's capacity will underpin the development and delivery of personalised solutions to individual patients. This will be very relevant to cancer patients so we expect that the VCCC will be at the vanguard of personalised medicine utilising approved health data connection techniques.



VCCC Uses BioGrid for Policy and Practice Research

In an Australian first, the Victorian Comprehensive Cancer Centre (VCCC) is appointing a Chair in Cancer Health Services Research to produce novel, high quality research to develop evidence to inform policy changes. This will be the first health services research program in Australia that is focussed on cancer.

Evidence resulting from research is of limited value if it cannot be put into action. Overseas experience has demonstrated that health service and system research directly impact on the cost efficiency of health services and on patient outcomes. A systematic program of outcome-focussed health service research will be undertaken and results used to deliver the highest standards of healthcare to cancer patients.

Cancer services in Victoria are often most inefficient at the boundaries of care, for example during transfer to and from hospital and into primary care. Lack of integration across healthcare sectors is widely cited as one reason for less than optimal health and wellbeing outcomes. So the VCCC is driving initiatives to improve evidence around cancer patient transitions by building research capacity and infrastructure for data-driven improvements in healthcare.

The VCCC will appoint a Chair through its “Leaders in Cancer” program, that aims to provide evidence to change policy, clinical practice and service delivery. Evidence based policy changes should lead to improvements in the quality, efficiency, cost and equity of cancer services.

To support this research program, the VCCC is creating a Cancer Health Data Platform designed for cancer health services research. This project will conduct the first large-scale, comprehensive data linkage to join primary care and hospital data for cancer patients. Each of the VCCC partner hospitals has agreed to contribute clinical and administrative data, which will be linked to the Victorian Cancer Registry to enable identification of cancer patients, and then to data from primary care. Linkage is via BioGrid and will be part of the collaboration with the Health and Biomedical Informatics Centre and the Department of General Practice at the University of Melbourne.

Until now, it has not been possible to extract detailed data from primary care services. Therefore, care given to cancer patients by primary care health professionals has been invisible to health services research. BioGrid’s unique data sharing infrastructure will be used to facilitate federated data sharing and ethical access to health service data.


The VCCC was recently awarded competitive funding from the BUPA Foundation for research that will use the Cancer Health Data Platform to investigate care given to cancer patient data at the three key points where the primary care and hospital systems intersect across the cancer journey:

- Diagnosis,
- During acute cancer treatment, and
- Post-cancer treatment follow up care.

This cancer health services research program will focus on:

- Factors associated with time from first presentation to primary carer to cancer diagnosis,
- Quantifying primary care use and the role of GPs in symptom management,
- Factors associated with GP visits during cancer treatment,
- Analysis of the patterns of follow up care for cancer survivors, and
- Assessing the management of co-morbidities and cancer screening of this population in primary care.

This research will provide evidence for changes in policy, clinical practice and service delivery at the points on the cancer journey when cancer patients intersect with the primary healthcare system. The evidence-based changes should improve the quality of cancer services.



BioGrid is Facilitating Diabetes Research across Australia

The BioGrid diabetes database is one of very few that collects primary care and/or secondary/tertiary care data regarding treatment, variations in care and treatment and outcomes. As a result, ten to 15 diabetes centres around the country have adopted the BioGrid database for data collection, clinical care, research and care quality assessment.

Why is this so important? The World Health Organisation released the following statistics about diabetes:

- Diabetes caused 1.5 million deaths during 2012
- During 2014, 422 million people in the world had diabetes – a prevalence of 8.5 per cent among the adult population
- The prevalence of diabetes has been steadily increasing for the past three decades and is growing most rapidly in low- and middle-income countries
- Diabetes is an important cause of blindness, kidney failure, lower limb amputation and other long-term consequences that impact significantly on quality of life

Only research into prevention and care can reduce this shocking burden of disease and reduce the death toll.

The BioGrid database has been nationally recognised as a useful data collection tool in multiple tertiary centres across the country. It is used for:

- Recruiting patients for research into new treatments for diabetes and its complications
- Assessment of quality and variation of care – an important factor in improving outcomes for people with diabetes
- Original research into aspects of treatment, development of complications and role of new treatments in public health
- Providing summary data to the Australian Diabetes Data Collection – used to identify quality and variation of care across diabetes centres across the country.

The availability of the database has already stimulated the development and funding of the Australian Diabetes Data Network (ADDN). Initially this network involved only paediatric sites caring for young people with type 1 diabetes. ADDN 2 will allow data to be collected via BioGrid for adult patients with type 1 diabetes. There are huge opportunities for research with the ADDN, which have been stimulated by BioGrid.

In future the BioGrid database will be expanded to include DNA and other biomarkers which can be used to better define complication risks and also treatment targets and pharmacogenomics relating to the development of new pharmaceuticals. The detailed BioGrid phenotypic data are unique in supporting this type of research into the future.

BioGrid is working with key clinicians to make the BioGrid diabetes database available to more diabetes centres around Australia as part of a National Association of Diabetes Centres (NADC) project. For NADC members, the database will serve as a patient medical record as well as a source of data for practice evaluation and quality audit. The Australian National Diabetes Audit relies on member centres to collect clinical data on a national biennial basis.

The BioGrid diabetes database will support relevant data collection and reporting that will allow each centre to benchmark their data against others. This NADC project was made available to NADC members during late 2014 and it is anticipated that during 2015 members will be collecting data using the BioGrid diabetes database within their diabetes clinics.



Roche Seeks Insights to Move towards Personalised Care

BioGrid has a strong history of working with the private sector to provide a unique look at the real life performance of drugs. Associate Professor Peter Gibbs is leading the metastatic colorectal cancer (mCRC) project, which has been particularly productive in 2014-15 with the publication of some important abstracts and four peer-reviewed papers.

The Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry, a database supported by Roche Products Pty Limited (Australia), was utilised for the project this year. Roche is supporting TRACC as part of its personalised healthcare strategy. The accompanying graphic on page 13 neatly summarises the achievements TRACC has supported.

Using a clinician defined data set TRACC is enabling data to be collected on all patients with mCRC, including those who do not receive any treatment, at a growing number of Australian and international sites. Survival outcome is recorded for all patients and for treated patients, details regarding all lines of treatment, including response and toxicity. Key data, such as performance status, are mandatory fields and co-morbidity data are collected on every patient. When individual research projects are undertaken additional data can be obtained by chart review. Data are de-identified and linked by BioGrid for purposes of analysis and reporting. BioGrid assists with statistical analysis.

Particular strengths of the TRACC registry are its inclusiveness, with data captured on elderly patients, those with a poor performance status and those not receiving treatment; all groups that are traditionally excluded from clinical trials. It also allows for the study of site specific variations. BioGrid can then enable analysis of variance in treatment practices and outcomes by state, hospital and setting. It is also used for statistical analysis.

It is important to note that no identifying individual site or individual data are provided to Roche – they only receive aggregated summary data, including overall accrual, adverse events and outcome data. Clinicians are able to use these data for any research projects of interest, with approval from Roche not being required.

During this year, clinicians from 24 sites across Australia have collaborated on the project. Between them they have entered 2,000 patients into TRACC.

New sites are being added all the time and with the support of Roche, including in Hong Kong during 2016. Additional patients are important to improve statistical power and as the Hong Kong sites are the first outside Australia to be added, this will also be the first time it will be possible to compare patients, management and outcomes across borders.

In an exciting development, BioGrid has secured funding until the end of 2018 to continue the project. It is anticipated that more clinicians will actively participate in the project, meaning that more patients' data will be added to TRACC and available for analysis. The information gathered will no doubt lead to more publications but the most important aspect of the on-going project is that Roche will be better placed to provide medicines and diagnostic tools to improve the quality of life and survival rates for patients.

ON TRACC

TO DELIVERING UNIQUE INSIGHT INTO EVOLVING CLINICAL PRACTICE IN AUSTRALIA

2009

DATA COLLECTION BEGAN



>2000

PATIENTS

ENROLLED TO DATE

28

INVESTIGATORS

ACTIVELY PARTICIPATING



6

STATES & TERRITORIES

WITH TRACC SITES

Further local and international expansion planned



>50

PRESENTATIONS

at local and international meetings
(39 posters, 10 oral, 2 abstracts)



6

PUBLICATIONS

BASED ON COLLECTED DATA



TRACC = Treatment of Recurrent and Advanced Colorectal Cancer; mCRC = metastatic colorectal cancer;



CART-WHEEL Retains its Consumer Focus

CART-WHEEL is the Centre for Analysis of Rare Tumours and also stands for: collect; analyse; research and treat.

It is BioGrid's patient-centred data collection portal and it is dedicated to the memory of Danny Pollak, who lost his life to Hemangioendothelioma (a rare vascular cancer), in 2008 after a 10 year struggle. Danny was the inspiration behind CART-WHEEL and his mother Cynthia has been the driving force behind it. Principal Investigator Associate Professor Clare Scott says

"Cynthia has devoted a large part of her life to building an international database for people with Hemangioendothelioma. She tirelessly worked to help build this ethically approved platform and helped us to establish international links so we can provide hope for people with rare cancers."

This year Cynthia has handed over to Jonathon Granek, an expert consumer, who is ensuring that CART-WHEEL retains a consumer perspective and remains 'consumer-led'.

Jonathon leads the international consumer push for research into Epithelioid Hemangioendothelioma (EHE) and he promotes consumer autonomy in research and treatment. He is driving an approach that will cross-match individual patient's tumours with cancer drugs already on the market. This challenging project is in its early stages and we hope to launch it next year.

This year BioGrid planned a quality-control analysis of consumer-entered data. A team was assembled, including medical oncologists, research scientists and a geneticist. A data-cut was planned after 220 patients had been enrolled. Next year analysis of the 220 cases will commence and data completeness and granularity will be examined.

Clinicians have sought the ability to augment patient-entered data. The Victorian Cancer Agency has provided funds to commence the development of a mechanism to allow doctors to interact with patient data,

but only with patients' consent. Patient-entered data will not be altered, rather it will be augmented by clinicians, with both data-sets (original and augmented) available to the relevant consumer. We expect the project to be completed next year.

Andrew Warden is another of our highly-motivated consumers and he is driving a project to improve the specificity of data entered by patients with Waldenström's Macroglobulinemia (WM). Andrew identified a need to include additional questions specific to his tumour group and he is working with Dr Judith Trotman and BioGrid to obtain funds to incorporate questions required for patients with WM. Andrew is a leader of the Australian WM support community and he will also work with the international WM Foundation to encourage patients to enter their data, for use in research.

During this incredibly busy year for CART-WHEEL, the need for a database specialising in rare gynaecological cancers was also identified. Given that 50 per cent of gynae tumours are classified as rare, this is a very important step. This year Dr Michelle Harrison assumed responsibility for the gynae cancer section of CART-WHEEL.

Dr Harrison has trialled a method, with patient consent, of incorporating clinical practice data into the CART-WHEEL dataset and the approach has worked. She has started working with the Clinical Trials Group, Australia New Zealand Gynaecological Oncology Group (ANZGOG, the peak national peak organisation for gynaecological cancer clinical trials in Australia) to develop a nation-wide approach to uniting research and clinical practice via CART-WHEEL.

Many exciting projects in the rare cancer space were initiated in 2014 and BioGrid will work with consumers and clinicians to bring the projects to fruition during 2015.



BioGrid's Student Placement Success

BioGrid has commenced supporting the development of health information and information technology students by providing work placements supervised by BioGrid staff. BioGrid is working with La Trobe University to support health information students as well as Melbourne Polytechnic (formerly known as NMIT) to support IT technology students.

This year BioGrid hosted two students from La Trobe University on professional practice placements. The placements provided students with the opportunity to develop their knowledge and skills in health information management.

The students, Shivakumar Hiremath Shivalingaiah and Yang Guo undertook six-week placements as part of their studies with the School of Public Health & Human Biosciences. They were supervised by BioGrid's head of data services, Leon Heffer, who found them both a pleasure to work with.

Following orientation, students completed a range of activities to allow them to meet the large number of educational objectives of the program. They were required to keep a weekly journal of activities and these clearly demonstrated that the students had a very busy time at BioGrid.

The first week generally involved introductions to the BioGrid team, familiarisation with the platform, developing an understanding of the extensive range of databases and learning about data governance and the ethics approval process.

Subsequent weeks differed for Yang and Shiva but both learned about the development of the Australian Comprehensive Cancer and Research Database (ACCORD), the use of SAS and they undertook individual projects.

Shiva focused on reviewing the head and neck data dictionary while Yang focused on the development of a conference presentation.

Both students displayed a professional approach and attitude throughout their placements and gained valuable knowledge and skills.

Yang and Shiva both felt well supported and that they learned valuable skills and knowledge. Shiva was pleased to have learned about project management and processes involved in data linkage and Yang gained actual skills in the use of data analysis tools and hands on experience in developing and maintaining databases.

In addition, BioGrid hosted Meghna Vania, an information technology student from Melbourne Polytechnic, on a practical placement for three months. Meghna, who undertook software development work, was supervised by Liang Wang, BioGrid's lead software engineer, and reported to Naomi Rafael, BioGrid's head of technology and systems.

Following orientation similar to the health information students, Meghna learnt how to use new tools for web application development, Meghna provided valuable input into the redevelopment of the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) Registry, particularly in regards to designing the framework and coding the data migration scripts for migrating from version 2 to version 3.

Like the health information students, Meghna took a professional approach to her work at BioGrid and during the three month placement, gained valuable knowledge and skills to enable her to transition to work in the Australian IT sector.

We wish all the students well in their future endeavours and are pleased that BioGrid could contribute to their knowledge base, particularly in relation to supporting health and medical research infrastructure and services in Australia.

Directors' Report

The names and details of the company's directors in office during the 2014-15 financial year and until the date of this report are as follows:



Professor Bryan Williams
PhD, Hon FRSNZ

Director and Chairman since March 2009

Institute Director and CEO, Hudson Institute of Medical Research, 2014–present

Director, Monash Institute of Medical Research (2006–2013)

Director, Pacific Edge Ltd (New Zealand) (2013–present)

Director, Pacific Edge Pty Ltd (Australia) (2008–present)

Director, Cancer Trials Australia Pty Ltd, (2009–2014)

Director and Chairman, MEI Pharma Inc. (2006–2013)

Member of the Victorian Cancer Agency Consultative Council (2009–2012)

Director, Centre for Cancer Research, Monash Institute of Medical Research (2006–2012)

Professor, Department of Genetics, Case Western Reserve University, Cleveland, USA, (1993–2005)

Chairman, Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation in Cleveland, USA, (1991–2005)



Mr Robert Merriel
BA, Grad Dip Psychology,
Grad Dip Accounting, CPA

**Director and Company Secretary
March 2009–December 2014**

Chief Financial Officer and Company Secretary, Hudson Institute of Medical Research, 2014–present

Director, BioGrid Australia Ltd (2009–2014)

Associate Director, Healthcare Management Advisors (2011–2014)

Director, BioComm Services Pty Ltd (2007–2011)

Director, Australian Technology Fund Pty Ltd (2004–2011)

Member, BioGrid Management Committee (2004–2011) Chairman, BioGrid Management Committee (2005–2009)



Dr Julian Clark
BSc (Hon), PhD, MAICD, FTSE

Director since March 2009

Head of Business Development, The Walter and Eliza Hall Institute of Medical Research, 2003–present

Director, Australian Genome Research Facility (2015–present)

Director, Catalyst Therapeutics Pty Ltd (2012–present)

Director, Cancer Trials Australia Pty Ltd (2009–present)

Director, BACE Therapeutics Pty Ltd (2009–present)

Chairman & Member, Sansom Institute Advisory Committee, University of South Australia (2006–present)

Director, Julian Clark Consulting Pty Ltd (1999–present)

Chief Executive Officer, Cancer Therapeutics CRC Pty Ltd (2007–2009)

Director, Alchemia Limited (2006–2008)

Director, Genera Biosystems Pty Ltd (2004–2007)

Director, Meditech Research Limited (2004–2006)



**Professor Fernando
Martin-Sanchez**
BSc, MSc, PhD Informatics,
PhD Medicine, FACHI

Director April 2013–September 2015

Chair, Health Informatics, Melbourne Medical School, The University of Melbourne and Head, Institute of Broadband Enabled Society and Biomedical Informatics Research Laboratory, 2011–present

Director, BioGrid Australia Ltd (2013–2015)

Director, Health and Biomedical Informatics Centre, The University of Melbourne (2013–present)

Associate Director, Institute of Broadband Enabled Society (2013–2014)

Director, Health Informatics Society of Australia (2011–2013)

Founding Director, Medical Bioinformatics Research Unit (1998–2011)

Director, Spanish Health Informatics Society (1995–2011)

Chief Information Officer, National Institute of Health Carlos III, Spain (1993–1998)

Vice-President, International Medical Informatics Association (2007–2013)



Mr Christopher Arnold
B Comm, MBA, FCPA,
FAIM, MAICD

Director since March 2014

Executive Director, Skin & Cancer Foundation Inc. 2010–present

Chairman, Human Variome Project International Ltd (2014–present)

Director, Human Variome Project International Ltd (2008–present)

Director, Christ Church Grammar Foundation (2012–present)

Director, Skin & Cancer Foundation Inc (2009–present)

Chairman, Telediagnostics Pty Ltd (2010–present)

Principal, Hodgson Associates (2009–present)

Director Philanthropy Australia (2003–2009)

Director Australian Communities Foundation (1999–2007)



Mr David Polonsky
B Bus, CA, TIA, MAICD

Director since January 2015

Director, Moore Stephens (Vic) Pty Ltd (formerly Nexia Melbourne Pty Ltd) 2011–present

Director, DRP Consulting Pty Ltd (1990–present)

Director, Private Ancillary Funds

Directors' Report

Meetings attended

The following outlines meetings held and attended by each of the Directors in 2014–2015.

Director	Board of Directors		Audit & Risk Committee	
	Held	Attended	Held	Attended
Bryan Williams	6	6		
Robert Merriel	3	3	1	1
Julian Clark	6	5	3	3
Fernando Martin-Sanchez	6	6		
Chris Arnold	6	5		
David Polonsky	2	2	2	2

The entity is incorporated under the *Corporations Act 2001* and is a company limited by guarantee. As such, no shares are issued or held by directors. If the entity is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the entity. At 30 June 2015 the number of members was 30.

Principal activities

The principal activities of the Company are data sharing that advances health research by linking privacy-protected and ethically approved clinical, imaging, biospecimen and genetic data among a wide network of health collaborators.

During the year there was no significant change in the nature of those activities.

Company's objectives

The company's objectives are to:

- Facilitate internationally competitive medical research into the causes of ill health and disease;
- Provide an ethically approved privacy-protected service to connect data sources;
- Invest in technology development to ensure ongoing alignment with leading technology that supports privacy-protected data connection; and
- Be sustainable in order to fulfill the company's vision and mission and to service the needs of its' members.

To achieve these objectives, the company:

- Supported the Victorian Department of Health and Victorian Cancer Agency by providing data linkage and data management services for state funded cancer research projects;
- Worked with key stakeholders in the health sector to facilitate major research projects in Victoria and Australia;

- Provided ongoing training and support for quality specialist staff committed to providing a technology platform that supports medical research through privacy-protected data connection; and
- Retained a business development focus targeting organisations with the resources to support project work with the company.

Key performance measures

The company measures its own performance through the use of both quantitative and qualitative benchmarks. The benchmarks are used by the directors to assess whether the company's short-term and long-term objectives are being achieved.

	2015		2014	
	Actual	Benchmark	Actual	Benchmark
Total Number of Members	30	33	28	28
Current Institution Ethics Approvals	35	36	35	35
Approved Active Research Projects	88	106	96	98
Journal Publications to Date	138	124	111	109
% Income from Membership Subscriptions	18%	19%	15%	18%

Dividends

The Company Constitution forbids the payment or distribution of any profits, income or assets to the members.

Critical accounting estimates and judgements

The financial report for the year ended 30 June 2015 has been prepared on a going concern basis, which contemplates continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business.

The Company incurred a loss from continuing operations for the reporting period of \$212,025 for the year ended 30 June 2015, as well as being in a net liability position of \$134,536 as at 30 June 2015.

Notwithstanding the above, the Directors believe it is appropriate to prepare the financial report on a going concern basis given the circumstances summarised below:

- The Company has traded profitably since the end of the financial year;
- The Directors are continuing to work with government (Federal and State), existing and potential customers and clients in industry to increase revenue and expand the services and operations of the Company within Australia and overseas;

- The Directors are continuing to work with key stakeholders who have and continue to show their support for the Company and its future operations;
- The Company remains the only collaboration network in Australia with the legal and ethical framework to enable the sharing of real-time health and medical data for research. Accordingly it is well positioned to take advantage of opportunities as they arise nationally and internationally; and
- The Company continues to develop and improve its national data linkage platform in collaboration with key suppliers using global vendor hardware and software.

Having considered the above factors, the Directors have conceded that there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

Should the Company be unable to continue as a going concern, it may be appropriate to realise its assets and discharge its liabilities at amounts different to those stated in the financial report.

Events subsequent to balance date

Since the end of the financial year, the Company has traded profitably, which has resulted in an improved position of the Company as at the date of signing this Report.

Directors' remuneration

The Directors did not receive remuneration from the Company with the exception of reimbursement of expenses relating to their director role.

Indemnification of officers and auditors

During the year the Company paid a premium in respect of a contract insuring the directors of the Company, the Company secretary and all executive officers of the Company and of any related body corporate against a liability incurred as such a director, secretary or executive officer to the extent permitted by the *Corporations Act 2001*. The Company has not otherwise, during or since the year, indemnified or agreed to indemnify an officer or auditor of the Company or of any related body corporate against a liability incurred as such an officer or auditor.

Environmental regulation

The company's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a State or Territory.

Proceedings on behalf of Company

No person has applied for leave of court to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

The Company was not a party to any such proceedings during the year.

Auditor's Independence Declaration

The lead auditor's independence declaration for the year ended 30 June 2015 has been received and can be found on page 20 of this report.

Signed in accordance with a resolution of the Board of Directors.

On behalf of the Directors.



Bryan Williams, Director
Melbourne, 15 January 2016

BioGrid Australia Limited

31 136 185 647

Auditor's Independence Declaration

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2015 there have been:

- a) no contraventions of the auditor independence requirements as set out in Section 60.40 of the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- b) no contraventions of any applicable code of professional conduct in relation to the audit.

Saward Dawson

Saward Dawson Chartered Accountants

[Signature]

Tim Flowers

Partner

Blackburn, Victoria 3130
15 January 2016

20 Albert Street / PO Box 256
Blackburn Victoria 3130
T: +61 3 9894 2500
F: +61 3 9894 1622
contact@sawarddawson.com.au

PRINCIPALS: Bruce Saward FCA Peter Shields FCA
Tim Flowers CA Joshua Morse CA
ASSOCIATE: Cathy Braun CA
CONSULTANT: Cliff Dawson FCA
Liability limited by a scheme approved under Professional Standards Legislation



Financial Report

Statement of Profit or Loss and Other Comprehensive Income

For the Year Ended 30 June 2015

	Note	2015 \$	2014 \$
Revenue	2	1,185,873	1,142,126
Depreciation		(11,050)	(9,504)
Professional fees		(37,839)	(44,441)
Consultant expenses		(1,075,589)	(1,117,481)
Bank charges		(1,286)	(365)
License fees		(181,272)	(197,762)
Administrative expenses		(85,295)	(123,303)
Other expenses		(5,567)	(9,867)
Surplus/(Deficit) from ordinary activities		(212,025)	(360,597)
Other comprehensive income			
Items that will not be reclassified subsequently to profit or loss		–	–
Items that will be reclassified subsequently to profit or loss when specific conditions are met		–	–
Total other comprehensive income for the year		–	–
Total comprehensive income for the year		(212,025)	(360,597)

Statement of Financial Position

As at 30 June 2015

	Note	2015 \$	2014 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	4	11,020	35,617
Trade and other receivables	5	349,856	146,474
Other assets	6	–	174,642
TOTAL CURRENT ASSETS		360,876	356,733
NON-CURRENT ASSETS			
Property, plant and equipment	7	10,495	21,545
TOTAL NON-CURRENT ASSETS		10,495	21,545
TOTAL ASSETS		371,371	378,278
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	8	474,407	300,789
Other liabilities	9	31,500	–
TOTAL CURRENT LIABILITIES		505,907	300,789
TOTAL LIABILITIES		505,907	300,789
NET ASSETS		(134,536)	77,489
EQUITY			
Reserves	10	–	83,000
Accumulated surpluses		(134,536)	(5,511)
TOTAL EQUITY		(134,536)	77,489

Statement of Changes in Equity

For the Year Ended 30 June 2015

2015	Accumulated Surpluses \$	General Reserves \$	Total \$
Balance at 1 July 2014	(5,511)	83,000	77,489
Deficit for the year	(212,025)	–	(212,025)
Transfer to/from general reserves	83,000	(83,000)	–
Balance at 30 June 2015	(134,536)	–	(134,536)

2014	Accumulated Surpluses \$	General Reserves \$	Total \$
Balance at 1 July 2013	355,086	83,000	438,086
Deficit for the year	(360,597)	–	(360,597)
Balance at 30 June 2014	(5,511)	83,000	77,489

Statement of Cash Flows

For the Year Ended 30 June 2015

	Note	2015 \$	2014 \$
CASH FROM OPERATING ACTIVITIES:			
Receipts from customers		1,176,019	1,484,060
Payments to suppliers and employees		(1,201,273)	(1,651,253)
Interest received		657	3,075
Net cash provided by (used in) operating activities	11	(24,597)	(164,118)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Acquisition of property, plant and equipment		–	(25,268)
Net cash used by investing activities		–	(25,268)
Net cash increase (decrease) in cash and cash equivalents		(24,597)	(189,386)
Cash and cash equivalents at beginning of year		35,617	225,003
Cash and cash equivalents at end of financial year	4	11,020	35,617

Notes to the Financial Statements

For the Year Ended 30 June 2015

Note 1 Accounting policies

(a) General information

The Directors have prepared the financial reports on the basis that the Company is a non-reporting entity because there are no users who are dependent on its general purpose financial reports. These financial reports are therefore special purpose financial reports that have been prepared in order to meet the requirements of the *Australian Charities and Not-For-Profit Commission Act 2012*. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

BioGrid Australia Limited is a company limited by guarantee, incorporated and domiciled in Australia. Such accounting policies are consistent with those of previous periods unless stated otherwise.

(b) Basis of preparation

The financial reports have been prepared in accordance with the requirements of the mandatory Australian Accounting Standards applicable to entities reporting under the *Australian Charities and Not-For-Profit Commission Act 2012* and the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members.

The financial reports, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs unless otherwise stated in notes. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise. The amounts presented in the financial statements have been rounded to the nearest dollar.

Note 1 Accounting policies continued

(c) Critical accounting estimates and judgements

The financial report for the year ended 30 June 2015 has been prepared on a going concern basis, which contemplates continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business.

The Company incurred a loss from continuing operations for the reporting period of \$212,025 for the year ended 30 June 2015, as well as being in a net liability position of \$134,536 as at 30 June 2015.

Notwithstanding the above, the Directors believe it is appropriate to prepare the financial report on a going concern basis given the circumstances summarised below:

- The Company has traded profitably since the end of the financial year.
- The Directors are continuing to work with government (Federal and State), existing and potential customers and clients in industry to increase revenue and expand the services and operations of the Company within Australia and overseas.
- The Directors are continuing to work with key stakeholders who have and continue to show their support for the Company and its future operations.
- The Company remains the only collaboration network in Australia with the legal and ethical framework to enable the sharing of real-time health and medical data for research. Accordingly it is well positioned to take advantage of opportunities as they arise nationally and internationally.
- The Company continues to develop and improve its national data linkage platform in collaboration with key suppliers using global vendor hardware and software.

Having considered the above factors, the Directors have conceded that there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

(d) Revenue

Revenue from the rendering of services is recognised upon delivery of the service to customers.

Grant revenue is recognised in the statement profit or loss and other comprehensive income when the entity obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the Company and the amount of the grant can be measured reliably.

Donations are recognised as revenue when received.

All revenue is stated net of the amount of goods and services tax (GST).

(e) Consultant expenses

Consultants expenses predominantly represents remuneration and related on-costs paid to Melbourne Health who provide operational assistance as the Company does not directly employ. Other consultants are also engaged on commercial terms by the Company from time to time to assist with specific projects and assignments.

(f) Property, plant and equipment

Plant and equipment

Plant and equipment are measured on the cost basis less depreciation and impairment losses. Cost includes expenditure that is directly attributable to the asset.

Depreciation

The depreciable amount of all plant and equipment is depreciated on a straight-line basis over the asset's useful life to BioGrid Australia Limited commencing from the time the asset is held ready for use.

(g) Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities in the statement of financial position.

(h) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

(i) Income taxes

No current or deferred income tax assets or liabilities have been raised by the Company as it is exempt from income tax under Division 50 of the Income Tax Assessment Act. The company is a registered charity under the Australian Charities and Not-for-Profits Commission.

(j) Comparative figures

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

(k) Trade and other payables

Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the Company during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

(l) New accounting standards for application in future periods

The AASB has issued new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods. The directors have decided against early adoption of these Standards, but do not expect the adoption of these standards to have any impact on the reported position or performance of the Company.

	Note	2015 \$	2014 \$
--	------	------------	------------

Note 2 Revenue

Operating revenue

– Government grants	350,000	300,000
– Commercial-led projects	493,405	582,000
– Investigator-led projects	124,043	71,753
– Member subscriptions	217,044	172,373
– Interest received	657	3,075
– Donations	600	241
– Other income	123	12,684
Total Revenue	1,185,872	1,142,127

Note 3 Surplus from ordinary activities

Expenses

Remuneration of auditor		
Auditing or reviewing the financial report	4,950	5,250
Other services	1,400	1,700
	6,350	6,950

Note 4 Cash and cash equivalents

Cash at bank	11,020	35,617
	11,020	35,617

Note 5 Trade and other receivables

CURRENT

Trade receivables	349,856	146,474
	349,856	146,474

	Note	2015 \$	2014 \$
Note 6 Other assets			
CURRENT			
Prepayments		–	174,642
		–	174,642

Note 7 Property, plant and equipment

Plant and equipment			
At cost		34,727	34,727
Accumulated depreciation		(24,232)	(13,182)
Total plant and equipment		10,495	21,545

Note 8 Trade and other payables

CURRENT			
Unsecured liabilities			
Trade payables		462,549	304,651
GST payable		(32,239)	(49,458)
Accruals		44,097	33,950
Other payables		–	11,646
		–	11,646
		474,407	300,789

Note 9 Other liabilities

Income in advance		31,500	–
Trade payables		31,500	–

Note 10 General reserve

The general reserve records funds set aside as a contingency should the company decide to wind up.

Note 11 Cash flow information

Reconciliation of cash flow from operations with net current year deficit			
Net deficit for the year		(212,025)	(360,597)
Cash flows excluded from surplus attributable to operating activities			
– Depreciation		11,050	9,503
Changes in assets and liabilities			
– (Increase)/decrease in trade and term receivables		(203,832)	207,323
– (Increase)/decrease in other assets		174,642	(174,642)
– (Increase)/decrease in trade payables		173,618	179,295
– Increase/(decrease) in other liabilities		31,500	(25,000)
		(24,597)	(164,118)

Note 12 Company details

The registered office of the Company is:

BioGrid Australia Limited
Level 8, CMR Building
Royal Melbourne Hospital
300 Grattan St,
Parkville Victoria 3052

Note 13 Members' guarantee

The Company is registered with the *Australian Charities* and *Not-For-Profit Commission* and is a company limited by guarantee. If the Company is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the Company. At 30 June 2015 the number of members was 31.

Directors' Declaration

The directors have determined that the Company is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies described in Note 1 to the financial statements.

The Directors of the Company declare that:

1. The financial report and notes, as set out on pages 16 to 27, are in accordance with the *Australian Charities* and *Not-For-Profit Commission Act 2012* and:
 - (a) comply with Accounting Standards applicable to BioGrid Australia Limited; and
 - (b) give a true and fair view of the company's financial position as at 30 June 2015 and of its performance for the year ended on that date in accordance with the accounting policies described in Note 1 to the financial report.
2. In the Directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable with the continuing support of creditors.

This declaration is made in accordance with a resolution of the Board of Directors.



Bryan Williams
Director

15 January 2016



Julian Clark
Director

Independent Audit Report to the Members of BioGrid Australia Limited

Report on the Financial Report

We have audited the accompanying financial report, being a special purpose financial report, of BioGrid Australia Limited (the Company), which comprises the statement of financial position as at 30 June 2015, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, a summary of significant accounting policies, other explanatory information and the directors' declaration.

Director's Responsibility for the Financial Report

The Directors of the Company are responsible for the preparation and fair presentation of the financial report and have determined that the accounting policies described in Note 1 to the financial report, are appropriate to meet the requirements of the *Australian Charities and Not-For-Profit Commission Act 2012* and are appropriate to meet the needs of the members. The Directors' responsibility also includes internal control as the Directors determine is necessary to enable the preparation of a financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We have conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.

Basis of Opinion

Qualification

We draw attention that the Company sustained a deficit of \$212,025 for the financial year ended 30 June 2015 and, as of that date, the Company's net asset position was in deficit of \$134,536. These conditions indicate the existence of a material uncertainty that casts significant doubt about the company's ability to continue as a going concern in the near future.

Auditor's Opinion

In our opinion, except for the effect on the financial statements of the matter referred to in the preceding paragraph, the financial report of BioGrid Australia Ltd is prepared in accordance with Division 60 of the Australian Charities and Not-for-Profits Commission Act 2012 including:

- giving a true and fair view of the Company's financial position as at 30 June 2015 and of its performance for the year then ended on that date; and
- complying with Australian Accounting Standards to the extent described in Note 1, and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Emphasis of Matter

Basis of Accounting

Without modifying our opinion, we draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report is prepared to assist BioGrid Australia Limited to meet the requirements of the *Australian Charities and Not-For-Profit Commission Act 2012*. As a result, the financial report may not be suitable for another purpose.

Saward Dawson Chartered Accountants



Tim Flowers
Partner

Blackburn, Victoria
15 January 2016

20 Albert Street / PO Box 256
Blackburn Victoria 3130
T: +61 3 9894 2500
F: +61 3 9894 1622
contact@sawarddawson.com.au

PRINCIPALS: Bruce Saward FCA Peter Shields FCA
Tim Flowers CA Joshua Morse CA
ASSOCIATE: Cathy Braun CA
CONSULTANT: Cliff Dawson FCA
Liability limited by a scheme approved under Professional Standards Legislation





BIOGRID AUSTRALIA

BioGrid Australia

ABN: 31 136 185 647

Level 8, CMR Building
The Royal Melbourne Hospital
300 Grattan Street
Parkville 3052
Victoria, Australia

T: +61 (0)3 9342 2690

F: +61 (0)3 9342 8548

enquiries@biogrid.org.au

www.biogrid.org.au

Design: Taylor & Grace

Published March 2016

Our Supporters

